Keywords: HIV, anti-inflammatory action, iodine-lithium-&, #945, -dextrin, IL&, #945, D monotherapy, quality of life, AIDS patients, clinical efficacy, tolerability, safety, phlebitis, subfebrile fever
Anti-HIV and anti-inflammatory action of iodine-lithium-α-dextrin is accompanied by the improved quality of life in AIDS patients
Clinical efficacy, tolerability and safety of various doses of Iodine-Lithium-α-Dextrin (ILαD) monotherapy have been evaluated in 56 HIV-infected patients enrolled in double blind uncontrolled randomised study during 48 weeks follow-up period. ILαD was administered intravenously three times over five days with intervals of 23 weeks between treatments for a total of 12 infusions in 4 cycles. HIV-1 RNA reduction and increase of CD4+ T-cell counts as well as decrease of serum levels of IgG, IgA, β2 microglobulin, tumour necrosis factor-α and soluble interleukin-2 receptor were observed on 424th weeks. Quality of life was dramatically improved on 448th weeks and more. The side-effects were phlebitis of punctured small veins and subfebrile fever, that did not lead to discontinuation of the treatment and did not require special treatment. ILαD appears to be safe and can be used as an adjuvant therapy for long term improvement of quality of life in AIDS patients.